• Molecular NameMontelukast
  • SynonymNA
  • Weight586.196
  • Drugbank_IDDB00471
  • ACS_NO158966-92-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)8.19
  • pkaN/A
  • LogD (pH=7, predicted)5.91
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-5.75
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds12
  • TPSA95.72
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability62.0
  • Protein binding99.0
  • Volume of distribution (VD)0.15 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMontelukast is metabolized by CYP3A4 and CYP2C9.
  • Half life4.9 h
  • ExcretionBiliary
  • Urinary Excretion<0.2
  • Clerance0.70 ml/min/kg
  • ToxicitySide effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A